Repro Med Systems, Inc (KRMD)

Etorro trading 970x250
Repro Med Systems, Inc (KRMD) Logo

About Repro Med Systems, Inc

Repro Med Systems, Inc., doing business as KORU Medical Systems, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. The company offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. It also provides education and training materials to clinicians, patients, and patient advocates. The company sells its products through direct sales and medical device distributors, as well as online. Repro Med Systems, Inc. was founded in 1980 and is headquartered in Chester, New York. Address: 24 Carpenter Road, Chester, NY, United States, 10918

Repro Med Systems, Inc News and around…

Latest news about Repro Med Systems, Inc (KRMD) common stock and company :

What You Need To Know About Repro Med Systems, Inc.'s (NASDAQ:KRMD) Investor Composition
10 May, 2022 Yahoo! Finance

Every investor in Repro Med Systems, Inc. ( NASDAQ:KRMD ) should be aware of the most powerful shareholder groups...

KORU Medical Systems Announces 2022 First Quarter Financial Results
04 May, 2022 FinancialContent

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today reported financial results for the first quarter ended March 31, 2022.

KORU Medical Systems Receives FDA 510(k) Clearance for Delivery of EMPAVELI® (pegcetacoplan), Expands European Label for FreedomEdge®
02 May, 2022 FinancialContent

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today announced 510k clearance for use of the KORU Medical FreedomEdge® infusion system to deliver pegcetacoplan 20 mL solution, branded as EMPAVELI® or Aspaveli® and commercialized by Apellis in the United States and by Sobi outside the United States.

KORU Medical Systems to Report First Quarter 2022 Financial Results on May 4, 2022
20 Apr, 2022 FinancialContent

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced that the Company will report first quarter 2022 financial results on Wednesday, May 4, 2022. KORU Medical’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.

KORU Medical Systems Appoints Brian Case As Chief Technology Officer
18 Apr, 2022 FinancialContent

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced the appointment of Brian Case, a veteran medical technology R&D leader with over 20 years of experience, as the Company’s new Chief Technology Officer. Mr. Case will lead product development and innovation as the Company defines and executes a technology strategy to support a global drug delivery portfolio.

Repro Med Systems, Inc. (NASDAQ:KRMD) drops to US$125m and insiders who purchased earlier this year lose another US$38k
28 Mar, 2022 Yahoo! Finance

Insiders who acquired US$108k worth of Repro Med Systems, Inc.'s ( NASDAQ:KRMD ) stock at an average price of US$4.30...

KORU Medical Systems Announces 2021 Q4 and Full Year Financial Results
02 Mar, 2022 FinancialContent

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today reported financial results for the fourth quarter and full year ended December 31, 2021.

Earnings Scheduled For March 2, 2022
02 Mar, 2022 FinancialContent

Companies Reporting Before The Bell • SIGNA Sports United (NYSE:SSU) is expected to report quarterly loss at $0.04 per ...

Preview: Repro-Med Systems's Earnings
01 Mar, 2022 FinancialContent

Repro-Med Systems (NASDAQ:KRMD) is set to give its latest quarterly earnings report on Wednesday, 2022-03-02. Here's what investors need ...

Analysts Estimate Repro Med Systems, Inc. (KRMD) to Report a Decline in Earnings: What to Look Out for
23 Feb, 2022 Yahoo! Finance

Repro Med Systems, Inc. (KRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CORRECTING and REPLACING KORU Medical Systems to Report Fourth Quarter and Full Year 2021 Financial Results on March 2, 2022
22 Feb, 2022 FinancialContent

First paragraph, first sentence of release dated February 16, 2022, should read: Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced that the Company will report fourth quarter and full year 2021 financial results on Wednesday, March 2, 2022. [instead of Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced that the Company will report fourth quarter and full year 2021 financial results on Wednesday, March 2, 2021.].

KRMD Crosses Above Average Analyst Target
07 Feb, 2022 FinancialContent

In recent trading, shares of Repro Med Systems, Inc. (KRMD) have crossed above the average analyst 12-month target price of $3.00, changing hands for $3.01/share..

Those who invested in Repro Med Systems (NASDAQ:KRMD) five years ago are up 523%
26 Jan, 2022 Yahoo! Finance

It might be of some concern to shareholders to see the Repro Med Systems, Inc. ( NASDAQ:KRMD ) share price down 16% in...

The Daily Biotech Pulse: Allakos Slips Negative Late-Stage Data, Pfizer & Merck Announce Fresh COVID Pill Deal With UK, Regulatory Setback For Takeda
22 Dec, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Allakos's Lirentelimab ...

12 Health Care Stocks Moving In Tuesday's After-Market Session
21 Dec, 2021 FinancialContent

Gainers BioRestorative Therapies (NASDAQ:BRTX) stock rose 27.35% to $5.82 during Tuesday's after-market session. This security traded ...

KORU Medical Systems Receives FDA 510(k) Clearance for the Use of the FREEDOM60® with Two Additional SCIg Drugs
21 Dec, 2021 FinancialContent

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced FDA 510(k) clearance that expands on-label use of the FREEDOM60 Infusion System to two additional subcutaneous Ig (SCIg) medications, Cutaquig®, manufactured by Octapharma, and Xembify®, manufactured by Grifols.

KORU Medical Systems to Unveil Updated Strategic Plan at Investor Day
01 Dec, 2021 FinancialContent

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced it will host an investor day to provide an update to its strategic plan.

12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Nov, 2021 FinancialContent

Gainers Sundial Growers (NASDAQ:SNDL) stock increased by 28.49% to $0.93 during Friday's pre-market session. The ...

91 Biggest Movers From Yesterday
12 Nov, 2021 FinancialContent

Gainers NuZee, Inc. (NASDAQ: NUZE) shares jumped 164.5% to settle at $5.29 on Thursday. NuZee manufacturing partner, Cuvee Coffee, ...

12 Health Care Stocks Moving In Thursday's Intraday Session
11 Nov, 2021 FinancialContent

Gainers Liquidia (NASDAQ:LQDA) stock increased by 17.49% to $4.97 during Thursday's regular session. Trading volume for Liquidia's ...

54 Stocks Moving In Thursday's Mid-Day Session
11 Nov, 2021 FinancialContent

Gainers Pioneer Power Solutions, Inc. (NASDAQ: PPSI) shares gained 42.6% to $9.68. Pioneer Power Solutions recently announced the ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session
11 Nov, 2021 FinancialContent

Gainers ADMA Biologics (NASDAQ:ADMA) shares moved upwards by 11.42% to $1.56 during Thursday's pre-market session. ...

The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts
11 Nov, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus MerckCommences ...

KORU Medical Shares Surge On FDA Approval For FreedomEdge Infusion Pump
11 Nov, 2021 FinancialContent

TheFDA gave 510k clearancetoRepro Med Systems IncdbaKORUMedical Systems(NASDAQ: KRMD) ...

KORU Medical Systems Announces 2021 Third Quarter Financial Results
10 Nov, 2021 FinancialContent

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today reported financial results for the third quarter ended September 30, 2021.

KORU Medical Announces FDA Clearance for Delivery of Hizentra® Prefilled Syringes
10 Nov, 2021 FinancialContent

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today announced 510k clearance for use of the KORU Medical FreedomEdge® infusion pump to deliver Hizentra® [immune globulin subcutaneous (human) 20% liquid] 20 mL prefilled syringes. Hizentra® is the most prescribed subcutaneous Ig product and the first to be available in a prefilled syringe format.

KORU Medical Systems to Participate in Two Upcoming Conferences
09 Nov, 2021 FinancialContent

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced its participation in two upcoming conferences, Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum and the 33rd Annual Piper Sandler Healthcare Conference.

KORU Medical Announces Collaboration With Gilero to Accelerate Innovation
08 Nov, 2021 FinancialContent

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing and commercialization of innovative and easy-to-use home infusion solutions, today announced its collaboration with Gilero, a medical device design and manufacturing company. Gilero offers unparalleled engineering and manufacturing solutions and has been a trusted partner for medical and drug delivery device companies for 20 years. The collaboration is part of KORU Medical’s strategic focus on innovation as the Company expands and evolves its at-home infusion products and portfolio.

KORU Medical Expands Senior Team to Accelerate Growth Strategy
01 Nov, 2021 FinancialContent

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced the appointment of two new leaders who will be responsible for key elements of the Company's growth strategy: Rob Cannon as the Company's new Vice President of Sales, and Brian Hertzog as the Company's new Vice President of BioPharma Business Development. Mr. Cannon will be responsible for U.S. sales and increasing the overall penetration of subcutaneous therapy for commercialized biopharmaceutical drugs. Mr. Hertzog will be responsible for leading biopharmaceutical business development and increasing the number of new biopharmaceutical drugs on the Freedom platform.

KORU Medical Systems to Report Third Quarter 2021 Financial Results on November 10, 2021
27 Oct, 2021 FinancialContent

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today announced that the Company will report third quarter 2021 financial results on Wednesday, November 10, 2021. KORU Medical’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.

Repro Med Systems, Inc (KRMD) is a NASDAQ Common Stock listed in , ,

970x250